Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Releases Data Suggesting Usefulness of Biomarker for Detection of Prostate Cancer

Premium

This story originally ran on June 30.

Australian diagnostics company HealthLinx released data last week suggesting the potential of one of its biomarkers for use as a prostate cancer diagnostic.

In a study using a well-defined set of 30 prostate cancer plasma samples and 14 male controls, researchers detected the biomarker – which HealthLinx, citing a need to protect ongoing patent applications, identified only as CM1 – in only three of the 14 control samples, while detecting elevated concentrations in 27 of the 30 prostate cancer samples.

"The company is in discussions with a group of clinicians who are reviewing the data with the view that a study will be designed to validate the diagnostic utility of our technology in a clinical environment," Nick Gatsios, managing director of HealthLinx, said in a statement.

Prostate-specific antigen is the most commonly used biomarker for prostate cancer diagnosis, but its relatively poor performance – specificity of 63.1 percent and sensitivity of 34.9 percent – makes alternative tests desirable. Based on the current market for PSA testing, there is a roughly $350 million market for prostate cancer testing in the US alone.

HealthLinx is also involved in a 1,150-patient trial to determine whether the addition of two new protein biomarkers would improve its five-biomarker ovarian cancer diagnostic OvPlex (PM 6/18/2010).